Patents Assigned to PVAC MEDICAL TECHNOLOGIES LTD
  • Patent number: 9962451
    Abstract: A composition for treating or preventing inflammatory-related conditions includes as an active principle a carrier which exhibits a plurality of a scavenger structure capable of mitigating the activity of a mediator of inflammatory-related conditions. The scavenger structure includes a nucleophilic center complying with the formula X1(—R?—)(—R?)mHn where: a) X1 is a single-bonded heteroatom selected amongst N, O and S and exhibits a free electron pair; b) m is 0 or 1 and n is 1 or 2; c) —R?— is a bivalent organic group providing attachment to the carrier via one of its free valences and to X1 at the other free valence; and d) R?— is a monovalent organic group attached to the X1 via its free valence. A method for treating or preventing inflammatory-related conditions in an individual suffering from such conditions includes: providing the composition; and contacting the mediator within or separate from the individual.
    Type: Grant
    Filed: February 25, 2016
    Date of Patent: May 8, 2018
    Assignee: PVAC MEDICAL TECHNOLOGIES LTD.
    Inventors: Tim Bowden, Kristoffer Bergman, Thomas Engstrand, Lennart Soderberg
  • Patent number: 9585987
    Abstract: A composition, which upon activation, spontaneously forms a cross-linked hydrogel in aqueous liquid, includes: a) a formulation containing a hyluronan (HA-formulation) which includes a hyaluronan backbone (HA backbone) and a plurality of a reactive substituent group (reactive HA substituent) which i) is directly attached to the HA backbone, and ii) exhibits the reactive HA-group, and b) a formulation of a homo-multifunctional cross-linking reagent (CLR-formulation) exhibiting a plurality of a reactive group (reactive CLR-group). The two reactive groups are selected as a pair of counterparts that mutually and selectively react with each other to form a linkage structure. The hydrogel contains a cross-linking structure which a) is attached to the hyaluronan via two or more of the linkage structure and is defined by the reagent. The cross-linking structure exhibits a plurality of hydroxyl groups. The composition can be used in vivo or ex vivo as a support matrix.
    Type: Grant
    Filed: February 13, 2009
    Date of Patent: March 7, 2017
    Assignee: PVAC MEDICAL TECHNOLOGIES LTD
    Inventors: Kristoffer Bergman, Tim Bowden, Thomas Engstrand, Jons Hilborn, Dmitri Ossipov